It is well established that androgen receptors are essential for PCa development, in such a way that therapeutic strategies have sought to inhibit androgenic synthesis at an intratumourally level (i.e., abiraterone) or in a more efficient way, inhibit AR signalling (i.e., enzalutamide) [5]. The gene discussed is AR; the disease is posterior cortical atrophy.